Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Harvard Bioscience (HBIO) EBT (2016 - 2025)

Historic EBT for Harvard Bioscience (HBIO) over the last 17 years, with Q3 2025 value amounting to -$1.1 million.

  • Harvard Bioscience's EBT rose 7474.95% to -$1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$53.6 million, marking a year-over-year decrease of 30119.78%. This contributed to the annual value of -$11.7 million for FY2024, which is 35637.72% down from last year.
  • Per Harvard Bioscience's latest filing, its EBT stood at -$1.1 million for Q3 2025, which was up 7474.95% from -$2.3 million recorded in Q2 2025.
  • Over the past 5 years, Harvard Bioscience's EBT peaked at $3.4 million during Q2 2022, and registered a low of -$50.8 million during Q1 2025.
  • In the last 5 years, Harvard Bioscience's EBT had a median value of -$1.1 million in 2023 and averaged -$4.1 million.
  • The largest annual percentage gain for Harvard Bioscience's EBT in the last 5 years was 64129.75% (2022), contrasted with its biggest fall of 1052222.22% (2022).
  • Quarter analysis of 5 years shows Harvard Bioscience's EBT stood at $1.1 million in 2021, then crashed by 178.87% to -$892000.0 in 2022, then dropped by 23.65% to -$1.1 million in 2023, then soared by 153.49% to $590000.0 in 2024, then crashed by 292.2% to -$1.1 million in 2025.
  • Its last three reported values are -$1.1 million in Q3 2025, -$2.3 million for Q2 2025, and -$50.8 million during Q1 2025.